Markers to Determine Arrhythmia Vulnerability in End Stage Heart Failure.

Completed

• Conditions: arrhythmia; heart failure; reduced heart function; 10007521

• Registration Number: NL-OMON39922
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Patients will be included if they are over 18 years and under 80 years and able to give informed consent.
Patients with end stage heart failure undergoing LVAD implantation.

Exclusion Criteria

Under 18 and over 80 years
The inclusion criteria includes only the study population.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Measurements of the electrophysiological, structural and (immuno) histological<br /><br>characteristics of mature ventricular cardiomyocytes and serum markers. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Potential electrical markers and biomarkers for arrhythmia vulnerability.</p><br>